These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 38681275

  • 21. New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report.
    Pachpande V, Mullangi S, Lekkala MR, Patel A.
    Cureus; 2022 Apr; 14(4):e24479. PubMed ID: 35651416
    [Abstract] [Full Text] [Related]

  • 22. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
    Fischer M, Amos S, Levy L, Pollack R.
    Harefuah; 2021 Oct 02; 160(10):657-662. PubMed ID: 34689435
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R, Veluswamy R, Allaire JC, Barnes G.
    Curr Med Res Opin; 2022 Aug 02; 38(8):1361-1368. PubMed ID: 35575164
    [Abstract] [Full Text] [Related]

  • 31. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug 02; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 32. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV, Pond GR, Abou Alaiwi S, Nassar AH, Flippot R, Curran C, Kilbridge KL, Wei XX, McGregor BA, Choueiri T, Harshman LC, Sonpavde G.
    J Immunother Cancer; 2020 Mar 02; 8(1):. PubMed ID: 32234849
    [Abstract] [Full Text] [Related]

  • 33. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M, VanderWalde AM, Yu X, Vidal GA, Tian GG.
    Clin Lung Cancer; 2022 Dec 02; 23(8):686-693. PubMed ID: 36050243
    [Abstract] [Full Text] [Related]

  • 34. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
    Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH.
    Endocrinol Diabetes Metab Case Rep; 2019 Mar 05; 2019():. PubMed ID: 30836329
    [Abstract] [Full Text] [Related]

  • 35. Baseline risk factors associated with immune related adverse events and atezolizumab.
    Madjar K, Mohindra R, Durán-Pacheco G, Rasul R, Essioux L, Maiya V, Chandler GS.
    Front Oncol; 2023 Mar 05; 13():1138305. PubMed ID: 36925916
    [Abstract] [Full Text] [Related]

  • 36. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
    Motomura Y, Urai S, Hirota Y, Takegawa N, Bando H, Yamamoto M, Fukuoka H, Tsuda M, Ogawa W.
    Diabetol Int; 2024 Jan 05; 15(1):130-134. PubMed ID: 38264226
    [Abstract] [Full Text] [Related]

  • 37. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 38. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul 19; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 39. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Price PW, Jao K, Schellenberg DD, Juergens R, Leighl N, Chu Q.
    Oncologist; 2020 Nov 19; 25(11):981-992. PubMed ID: 32860288
    [Abstract] [Full Text] [Related]

  • 40. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL, Wang DY, Hu JX, Tian RY, Wang W, Su Q, Li H, Wang YL.
    Ocul Immunol Inflamm; 2022 Aug 19; 30(6):1449-1459. PubMed ID: 33970759
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.